Enhancement of Gene Transfer & Prostate Cancer Immunity

增强基因转移

• 批准号: 7067578
• 负责人: Timothy L. Ratliff
• 金额: $ 32.05万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-15 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7067578
• 关键词: Adenoviridae; T lymphocyte; antigen presenting cell; biodegradable product; clinical research; clinical trial phase I; collagen; gene delivery system; gene expression; gene therapy; human genetic material tag; human subject; human therapy evaluation; immunomodulators; male; neoplasm /cancer immunotherapy; patient oriented research; platelet activation; prostate neoplasms; prostate specific antigen; transfection /expression vector

DESCRIPTION (provided by applicant): Many strategies to develop new treatments for hormone independent prostate cancer are being investigated, including gene therapy and immunotherapy. While immune activation and antitumor responses have been enhanced by the utilization of gene transfer techniques, the development of immunotherapy regimens capable of eliminating tumors has been problematic. Many reasons for the weak immunotherapy responses have been advocated including inefficient gene transfer. In preliminary studies, we utilized Gelfoam as a biodegradable collagen delivery system (CODES) that was observed to enhance gene transfer in solid tumors and benign dog prostate. Moreover, CODES-mediated gene transfer augmented T cell immunity, significantly enhancing antitumor activity against established prostate cancers. The studies outlined in this application will evaluate the mechanisms by which CODES functions in animal models, and also will test the ability of CODES to enhance gene transfer and augment immunity in prostate cancer patients. Preliminary studies showed CODES to induce expression and release of immunomodulatory factors by platelets, which modulated immunity and gene expression, suggesting a link between CODES, platelet-derived innate immune mediators, and adaptive T cell immunity. If validated, the observation will, for the first time, link platelet activation to the activation of adaptive immunity. Moreover, it may provide a basis for the development of novel ways to enhance gene transfer and augment tumor immunity as well as add to current knowledge of factors capable of modulating immune response to foreign antigens. Studies translating the observations with CODES in animal models into clinical trials will test the hypothesis that CODES enhances gene delivery in human prostate tissue using E1A/E1B-deleted type 5 adenovirus carrying the gene for human tumor necrosis factor-related apoptosis-inducing ligand (Ad5-TRAIL). A second clinical study testing the hypothesis that CODES augments immunity in prostate cancer patients will be performed using adenovirus carrying the gene for prostate specific antigen.

描述（由申请人提供）：正在研究开发激素非依赖性前列腺癌新治疗方法的许多策略，包括基因治疗和免疫治疗。 虽然免疫激活和抗肿瘤反应已通过利用基因转移技术得到增强，但能够消除肿瘤的免疫治疗方案的开发一直存在问题。 免疫治疗反应弱的原因有很多，包括基因转移效率低。 在初步研究中，我们利用Gelfoam作为可生物降解的胶原蛋白递送系统（CODES），观察到其在实体瘤和良性犬前列腺中增强基因转移。 此外，CODES介导的基因转移增强了T细胞免疫力，显著增强了对已建立的前列腺癌的抗肿瘤活性。 本申请中概述的研究将评估CODES在动物模型中发挥作用的机制，并将测试CODES增强前列腺癌患者基因转移和增强免疫力的能力。 初步研究表明，CODES诱导血小板表达和释放免疫调节因子，调节免疫和基因表达，表明CODES，血小板衍生的先天免疫介质和适应性T细胞免疫之间的联系。 如果得到证实，这一观察结果将首次将血小板活化与适应性免疫的活化联系起来。 此外，它可能为开发新的方法来增强基因转移和增强肿瘤免疫力提供了基础，并增加了目前对能够调节对外源抗原的免疫反应的因素的认识。 将CODES在动物模型中的观察结果转化为临床试验的研究将测试CODES使用携带人肿瘤坏死因子相关凋亡诱导配体（Ad 5-TRAIL）基因的E1 A/E1 B缺失的5型腺病毒增强人前列腺组织中的基因递送的假设。 第二项临床研究将使用携带前列腺特异性抗原基因的腺病毒进行，以检验CODES增强前列腺癌患者免疫力的假设。